IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Rhea-AI Summary
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's CEO and co-founder, William Ho, will deliver a presentation on Tuesday, February 25, 2025, at 11:00 a.m. ET.
The presentation will be accessible through a live webcast, with a replay option available afterward. Interested parties can access the webcast through the provided link or find it in the 'Events and Presentations' section under News & Presentations on IN8bio's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, INAB gained 0.15%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the:
H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Date/Time Tuesday, February 25, 2025, at 11:00 a.m. ET.
Webcast Link https://journey.ct.events/view/acb6057e-9d9b-427e-b490-eaf85a5c2910
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investor & Corporate Contact
Glenn Schulman, PharmD, MPH
IN8bio, Inc.
203.494.7411
gdschulman@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
When is IN8bio (INAB) presenting at the H.C. Wainwright Cell Therapy Conference 2025?
How can investors watch IN8bio's presentation at the H.C. Wainwright conference?
What type of therapies does IN8bio (INAB) specialize in?
Will there be a replay available of IN8bio's H.C. Wainwright conference presentation?
